Beyond amyloid: New approaches to Alzheimer's disease treatment

In March, 2019, Biogen announced its decision to halt further research on its amyloid-targeting antibody, aducanumab, on the basis of interim futility analyses from two identically designed, phase 3 randomised controlled trials—EMERGE and ENGAGE. In a stunning subsequent announcement in October, the company reversed course, indicating they would be now be seeking US Food and Drug Administration approval of aducanumab on the basis of analyses of a larger dataset from the trials. On Dec 5, 2019, results from both randomised controlled trials were presented at the 12th Clinical Trials on Alzheimer's Disease conference in San Diego (CA, USA).